Inactivation of PI(3)K p110
Menée à l'aide d'un modèle murin, cette étude met en évidence des mécanismes immunitaires suggérant l'intérêt d'une stratégie basée sur l'inhibition de l'isoforme p110
Inhibitors against the p110
δ isoform of phosphoinositide-3-OH kinase (PI(3)K) have shown remarkable therapeutic efficacy in some human leukaemias. As p110δ is primarily expressed in leukocytes, drugs against p110δ have not been considered for the treatment of solid tumours. Here we report that p110δ inactivation in mice protects against a broad range of cancers, including non-haematological solid tumours. We demonstrate that p110δ inactivation in regulatory T
cells unleashes CD8+ cytotoxic T cells and induces tumour regression. Thus, p110
δ inhibitors can break tumour-induced immune tolerance and should be considered for wider use in oncology.